Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer / Ferro, M., Barone, B., Crocetto, F., Lucarelli, G., Busetto, G.M., Del Giudice, F., Maggi, M., Crocerossa, F., Cantiello, F., Damiano, R., Borghesi, M., Bove, P.L., Papalia, R., Mari, A., Luzzago, S., Soria, F., Marchioni, M., La Civita, E., Terracciano, D., Mistretta, F.A., et al.. - In: UROLOGIC ONCOLOGY. - ISSN 1078-1439. - 40:11(2022), pp. 13-20. [10.1016/j.urolonc.2022.05.016]
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer
Lucarelli, Giuseppe;Busetto, Gian Maria;Del Giudice, Francesco;Maggi, Martina;Mari, Andrea;Schips, Luigi;
2022
Abstract
Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ferro_Predictive clinico-pathological_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
690.96 kB
Formato
Adobe PDF
|
690.96 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
